Momelotinib for treating myelofibrosis-related splenomegaly or symptoms

Register of interests (PDF 152 KB)

Final draft guidance

Final draft guidance (PDF 215 KB)

Committee papers (PDF 8.49 MB)

Public committee slides (PDF 1.52 MB)

Equality impact assessment (PDF Version) (PDF 145 KB)

Final scope (PDF 192 KB)

Final stakeholder list (PDF 165 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 242 KB)

Equality impact assessment (Scoping) (PDF 125 KB)

Draft scope post referral (PDF 177 KB)

Draft matrix post referral (PDF 162 KB)